Scientists used 3D mini-brains grown from stem cells to study Huntington’s disease. They found early developmental changes ...

Participants in a PET study received the tracer, then gave it time to reach the brain. Then they laid in a scanner that took ...

Picture a quiet neighborhood. Things used to run smoothly here. Kids played outside, front yards were mowed, and the neurons — the longtime residents — looked out for one another. But lately, fires ...

June was filled with exciting research! Ranging from clinical trial updates to irritability, we’ve rounded up the most exciting Huntington’s disease research from this month.

Minocycline: the end of the road? DOMINO clinical trial result: minocycline doesn’t slow down HD and shouldn’t be studied in larger trials.

TRACK-HD reveals significant changes in pre-symptomatic HD mutation carriers and patients The one-year report from the TRACK-HD study demonstrates a number of changes in pre-symptomatic HD-mutation ...

Scientists tested a new tool to measure harmful HTT protein in HD. It wasn’t perfect, but offered key insights to guide better tools already in the works. A big step toward tracking HD non-invasively, ...

The HDBuzz team recently convened in Palm Springs, California, along with hundreds of other scientists from all over the globe, for the 19th Annual HD Therapeutics Conference, hosted by the HD ...

Dr. Leora Fox works at the Huntington's Disease Society of America, which has relationships and non-disclosure agreements with pharmaceutical companies, including Wave Life Sciences and Roche. Rachel ...

Roche gave an update this week about GENERATION HD2, testing the HTT-lowering drug tominersen in people with HD. The trial is continuing, but only the higher dose will move forward. What does this ...